Johnson & Johnson in talks to acquire Protagonist Therapeutics, source says
PositiveFinancial Markets

Johnson & Johnson is reportedly in discussions to acquire Protagonist Therapeutics, a move that could significantly enhance its portfolio in the pharmaceutical sector. This acquisition is important as it reflects J&J's strategy to bolster its research and development capabilities, particularly in innovative therapies. If successful, this deal could lead to new treatments and advancements in healthcare, benefiting patients and investors alike.
— Curated by the World Pulse Now AI Editorial System